A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral
administration balovaptan once a day (QD) compared with matching placebo in adults (18 years
and older) with autism spectrum disorder (ASD).